Evaluation of serum amyloid a as a biomarker for gastric cancer

De-Chuan Chan, Cheng-Jueng Chen, Heng-Cheng Chu, Wei-Kuo Chang, Jyh-Cherng Yu, Yu-Ju Chen, Li-Li Wen, Su-Ching Huang, Chih-Hung Ku, Yao-Chi Liu, Jenn-Han Chen

研究成果: 雜誌貢獻文章同行評審

83 引文 斯高帕斯(Scopus)

摘要

Background: Serum amyloid A (SAA) is a useful biomarker for gastric cancer in an animal model. We investigated the potential of SAA as a biomarker for gastric cancer in humans. Methods: Serum levels of SAA from 96 gastric cancer patients were measured before and after curative gastrectomy; 32 patients with gastric ulcers and 52 healthy subjects were the control groups. The immunohistochemical study was performed to evaluate the protein expression over gastric cancer tissue slides. Results: The mean SAA concentration was higher in gastric cancer patients (88.54 ± 50.44 mg/l) than in healthy subjects (3.36 ± 2.29 mg/l) and gastric ulcer patients (10.48 ± 8.97 mg/l) (P <.05). The SAA concentration was associated with tumor stage (P = .0244) and location (P = .0016) but not with Lauren's histological type (P = .839). In the multivariate analysis, SAA level was correlated with tumor location (P <.0001) and lymph node status (P <.05). During follow-up, the mean SAA concentration increased significantly in 24 patients with tumor recurrence (P <.05) but did not change in 77 patients without recurrence. In the survival analysis, patients with SAA levels > 97 mg/l had a nearly fourfold increase in risk of death. Immunoreactivity was most prominent in blood vessel regions but not within cancer cells. Conclusions: These data not only demonstrated SAA was useful in predicting survival of patients with gastric cancer, but they also showed that SAA was a valuable tool for postoperative follow-up. © 2006 Society of Surgical Oncology.
原文英語
頁(從 - 到)84-93
頁數10
期刊Annals of Surgical Oncology
14
發行號1
DOIs
出版狀態已發佈 - 2007
對外發佈

指紋

深入研究「Evaluation of serum amyloid a as a biomarker for gastric cancer」主題。共同形成了獨特的指紋。

引用此